Democratizing hedge fund level analysis tools for everyone
| Name | Millennium Pharmacon International Tbk. |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Health Care Research |
| Code | F2 |
| Latest Quarterly | 06-30-25 |
| Name | Latest % | A Month Ago % |
|---|---|---|
| Pharmaniaga International Corporation Sdn. Bhd. | 73.43 | 73.43 |
| Public < 5% | 16.85 | 16.85 |
| PT. Danpac Pharma | 9.72 | 9.72 |
| Source | 2022 | 2021 |
|---|---|---|
| SDPC | F2 | Prescription Medicine |
| SDPC | F2 | Medical Devices |
| SDPC | F2 | Non-prescription Medicine |
| SDPC | F2 | Others |
| SDPC | F2 | Other |
| Region | 2022 | 2021 |
|---|---|---|
| SDPC | F2 | Indonesia |
| SDPC | F2 | Others |
| Valuation | Ratio | Rank |
|---|---|---|
| P/S | 0.05 | # 1 / 15 |
| EV_EBITDA | 13.62 | # 9 / 15 |
| PER | 7.32 | --- / 15 |
| PBV | 0.64 | # 1 / 15 |
| DER | 5.34 | # 13 / 15 |
| Profitability | Ratio | Rank |
|---|---|---|
| NPM % | 0.679 | # 10 / 15 |
| ROA % | 1.43 | # 10 / 15 |
| ROE % | 8.9 | # 11 / 15 |
| Year | DPS | Yield [%] |
|---|---|---|
| 2024 | 5.0 | 3.8 |
| 2023 | 4.0 | 2.6 |
| 2022 | 2.0 | 0.6 |
| 2021 | 1.0 | 0.8 |
| 2020 | 2.0 | 2.0 |
| 2019 | 6.0 | 6.4 |
| Timeframe | Performance |
|---|---|
| 1W % | -5.6 |
| 1Mo % | 10.1 |
| 3Mo % | 12.5 |
| 1Yr % | 16.8 |
| Stocks | PER | Market Cap | EV | Revenue | EBITDA | Net Profit |
|---|---|---|---|---|---|---|
| KLBF | 16.21 | 56.88 T | 58.14 T | 34,651 B | 5,348 B | 3,508 B |
| SOHO | 30.18 | 17.51 T | 19.64 T | 10,338 B | 711 B | 581 B |
| SIDO | 14.84 | 16.20 T | 15.77 T | 3,639 B | 1,481 B | 1,091 B |
| TSPC | 8.20 | 12.45 T | 10.93 T | 13,512 B | 2,016 B | 1,515 B |
| PYFA | -11.02 | 5.39 T | 11.42 T | 2,747 B | -142 B | -488 B |
| MDLA | 9.50 | 3.67 T | 6.27 T | 14,788 B | 557 B | 386 B |